157 related articles for article (PubMed ID: 36341193)
1. Efficacy of combination therapy with pembrolizumab and axitinib for metastatic renal collecting duct cell carcinoma: A report on two cases.
Tamada S; Ikarashi D; Tsuyukubo T; Iwasaki K; Isurugi K; Ono S; Takata R; Fujisawa H; Obara W
IJU Case Rep; 2022 Nov; 5(6):438-441. PubMed ID: 36341193
[TBL] [Abstract][Full Text] [Related]
2. A case of an advanced renal collecting duct carcinoma in which initial therapeutic effect was achieved with pembrolizumab plus axitinib.
Atagi Y; Daizumoto K; Mohri S; Somiya K; Seto D; Nakanishi S; Yanagihara Y; Ninomiya I; Okamoto K; Yamashi S
IJU Case Rep; 2024 Jan; 7(1):50-55. PubMed ID: 38173448
[TBL] [Abstract][Full Text] [Related]
3. Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report.
Katsumata Y; Kawasaki Y; Tanaka K; Nakayama D; Katayama H; Shimada S; Satake Y; Sato T; Kawamorita N; Yamashita S; Sato T; Shoji K; Mitsuzuka K; Ito A
Case Rep Oncol; 2021; 14(3):1522-1529. PubMed ID: 34899246
[TBL] [Abstract][Full Text] [Related]
4. Extrarenal multiorgan metastases of collecting duct carcinoma of the kidney: a case series.
Nakamura H; Kuirhara Y; Matsushita K; Sakai A; Yamaguchi T; Nakajima Y
J Med Case Rep; 2008 Sep; 2():304. PubMed ID: 18798981
[TBL] [Abstract][Full Text] [Related]
5. Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long-term treatment-free survival with pembrolizumab and axitinib in the KEYNOTE-426 phase III trial of pembrolizumab and axitinib versus sunitinib.
Nishimoto K; Shirotake S; Miyama Y; Kaneko G; Kanao K; Igarashi D; Takahashi T; Umezawa Y; Yasuda M; Oyama M
IJU Case Rep; 2022 May; 5(3):149-152. PubMed ID: 35509782
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Rini BI; Plimack ER; Stus V; Gafanov R; Hawkins R; Nosov D; Pouliot F; Alekseev B; Soulières D; Melichar B; Vynnychenko I; Kryzhanivska A; Bondarenko I; Azevedo SJ; Borchiellini D; Szczylik C; Markus M; McDermott RS; Bedke J; Tartas S; Chang YH; Tamada S; Shou Q; Perini RF; Chen M; Atkins MB; Powles T;
N Engl J Med; 2019 Mar; 380(12):1116-1127. PubMed ID: 30779529
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
[TBL] [Abstract][Full Text] [Related]
8. Immune-related dermatitis during combined treatment with pembrolizumab and axitinib in a patient with metastatic renal cell\x92carcinoma with stasis dermatitis.
Imai S; Nakamura M; Chujo S; Ooki R; Inoue Y; Horiuchi H; Morikawa T; Uchino K; Igarashi A; Shiga Y
IJU Case Rep; 2021 Nov; 4(6):386-390. PubMed ID: 34755064
[TBL] [Abstract][Full Text] [Related]
9. [COMPLETE REMISSION OF METASTATIC RENAL CELL CARCINOMA AFTER PARTIAL NEPHRECTOMY FOLLOWING PEMBROLIZUMAB PLUS AXITINIB THERAPY: A CASE REPORT].
Hakamata Y; Uchida K; Noda T; Imai S; Yoneda T; Kudoh S
Nihon Hinyokika Gakkai Zasshi; 2022; 113(4):139-142. PubMed ID: 37866934
[TBL] [Abstract][Full Text] [Related]
10. A case of hyperammonemia occurring during treatment of metastatic renal cell carcinoma with axitinib.
Kimura S; Fujisaki Y; Onizuka C; Hasuike S; Sato Y; Mukai S; Kamoto T
IJU Case Rep; 2023 Jul; 6(4):206-210. PubMed ID: 37405030
[TBL] [Abstract][Full Text] [Related]
11. Pathologic complete response with pembrolizumab plus axitinib in metastatic renal cell carcinoma.
Shimizu K; Tamada S; Matsuoka Y; Go I; Okumura S; Ogawa M; Ohmachi T
Int Cancer Conf J; 2022 Jul; 11(3):205-209. PubMed ID: 35669898
[TBL] [Abstract][Full Text] [Related]
12. Pathological Complete Response of Metastatic Clear Cell Renal Carcinoma with Pembrolizumab and Axitinib: A Case Report and Review of Literature.
Beirat AF; Menakuru SR; Khan I; Siddiqui S
Case Rep Oncol; 2023; 16(1):30-35. PubMed ID: 36743880
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
Watson TR; Gao X; Reynolds KL; Kong CY
JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date.
Chau V; Bilusic M
Cancer Manag Res; 2020; 12():7321-7330. PubMed ID: 32884346
[TBL] [Abstract][Full Text] [Related]
15. Hypopituitarism induced by pembrolizumab plus axitinib in the treatment of metastatic renal cell carcinoma: A case report.
Hanawa K; Sawada N; Aikawa J; Otake Y; Kasai Y; Mochizuki K; Shimura H; Mochizuki T; Kira S; Mitsui T
Oncol Lett; 2024 Feb; 27(2):66. PubMed ID: 38192652
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma.
Spisarová M; Melichar B; Vitásková D; Študentová H
Expert Rev Anticancer Ther; 2021 Jul; 21(7):693-703. PubMed ID: 33794744
[No Abstract] [Full Text] [Related]
17. Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.
Ding D; Hu H; Shi Y; She L; Yao L; Zhu Y; Zeng S; Shen L; Huang J
Oncologist; 2021 Feb; 26(2):e290-e297. PubMed ID: 32918790
[TBL] [Abstract][Full Text] [Related]
18. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
[TBL] [Abstract][Full Text] [Related]
19. Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States.
Zakharia Y; Thomaidou D; Li B; Siu G; Levin R; Vlahiotis A; Rao D; Zanotti G
Front Oncol; 2022; 12():861189. PubMed ID: 35664758
[TBL] [Abstract][Full Text] [Related]
20. A patient with advanced lung squamous cell carcinoma who failed to benefit from albumin bound paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus pembrolizumab: a case report.
Zhang F; Xu Y; Guo S; Li S; Ma K; Wang J; Wei S
Ann Palliat Med; 2022 Sep; 11(9):3020-3027. PubMed ID: 36217630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
